Standard

Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants. / Belgian Collaborative Group on COVID-19 hospital surveillance.

In: International Journal of Antimicrobial Agents, Vol. 56, Nr. 4, 2020, blz. 106144.

Onderzoeksoutput: Bijdrage aan tijdschriftA1: Web of Science-artikel

Harvard

Belgian Collaborative Group on COVID-19 hospital surveillance 2020, 'Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants', International Journal of Antimicrobial Agents, vol. 56, nr. 4, blz. 106144. https://doi.org/10.1016/j.ijantimicag.2020.106144

APA

Belgian Collaborative Group on COVID-19 hospital surveillance (2020). Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants. International Journal of Antimicrobial Agents, 56(4), 106144. https://doi.org/10.1016/j.ijantimicag.2020.106144

Vancouver

Belgian Collaborative Group on COVID-19 hospital surveillance. Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants. International Journal of Antimicrobial Agents. 2020;56(4):106144. https://doi.org/10.1016/j.ijantimicag.2020.106144

Author

Belgian Collaborative Group on COVID-19 hospital surveillance. / Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants. In: International Journal of Antimicrobial Agents. 2020 ; Vol. 56, Nr. 4. blz. 106144.

BibTeX

@article{bfa37fbe28ca433b97c3aa39069b8525,
title = "Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants",
abstract = "Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7{\%}) and 957/3533 (27.1{\%}), respectively. In the multivariable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95{\%} confidence interval (CI) 0.617-0.758]. Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95{\%} CI 0.617-0.796) and aHR = 0.647 (95{\%} CI 0.525-0.797), respectively]. Compared with supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset.",
author = "{Belgian Collaborative Group on COVID-19 hospital surveillance} and Lucy Catteau and Nicolas Dauby and Marion Montourcy and Emmanuel Bottieau and Joris Hautekiet and Els Goetghebeur and {van Ierssel}, Sabrina and Els Duysburgh and {Van Oyen}, Herman and Chlo{\'e} Wyndham-Thomas and {Van Beckhoven}, Dominique",
note = "CPDF; Copyright {\circledC} 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.",
year = "2020",
doi = "10.1016/j.ijantimicag.2020.106144",
language = "English",
volume = "56",
pages = "106144",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants

AU - Belgian Collaborative Group on COVID-19 hospital surveillance

AU - Catteau, Lucy

AU - Dauby, Nicolas

AU - Montourcy, Marion

AU - Bottieau, Emmanuel

AU - Hautekiet, Joris

AU - Goetghebeur, Els

AU - van Ierssel, Sabrina

AU - Duysburgh, Els

AU - Van Oyen, Herman

AU - Wyndham-Thomas, Chloé

AU - Van Beckhoven, Dominique

N1 - CPDF; Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

PY - 2020

Y1 - 2020

N2 - Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95% confidence interval (CI) 0.617-0.758]. Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95% CI 0.617-0.796) and aHR = 0.647 (95% CI 0.525-0.797), respectively]. Compared with supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset.

AB - Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95% confidence interval (CI) 0.617-0.758]. Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95% CI 0.617-0.796) and aHR = 0.647 (95% CI 0.525-0.797), respectively]. Compared with supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset.

U2 - 10.1016/j.ijantimicag.2020.106144

DO - 10.1016/j.ijantimicag.2020.106144

M3 - A1: Web of Science-article

C2 - 32853673

VL - 56

SP - 106144

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 4

ER -

ID: 12481241